DELRAY BEACH, Fla. , Sept. 27, 2024 /PRNewswire/ -- The global Age-related Macular Degeneration drugs market is set to grow from USD 10.
46 billion in 2024 to USD 17.37 billion by 2029, reflecting a robust CAGR of 10.7%.
This growth is driven by rising AMD prevalence linked to lifestyle changes, increased R&D investment leading to more drug approvals, and improved reimbursement policies. The market is particularly expanding in developing countries and is witnessing a shift towards innovative therapies like gene therapy. However, challenges like high treatment costs and the off-label use of drugs such as Avastin hinder market potential.
Notably, Eylea remains the leading product, while dry AMD therapies are expected to grow rapidly due to escalating cases among the aging population. North America is projected to be the fastest-growing region, with significant annual AMD case increases. Key players include Regeneron, Bayer, and Novartis, among others, with recent developments indicating a strong focus on new therapeutic solutions.
.